Nln-pcr standard for breast cancer treatment

In the treatment of breast cancer, new assisted treatment (Neoadjuvant Therapy, NAT) usually refers to systematic treatment before the operation, including chemotherapy, target-oriented treatment or endocrine treatment, aimed at reducing tumours and tumours, thus increasing the success of the operation and the survival of the patient. An important indicator of the assessment of the treatment response after the new assisted treatment is the state of non-pathological complete decomposition (Non-patholonic Complete Reponese, NON-pCR), which means that after the treatment, although the tumour has decreased, it has not achieved a full pathological decomposition (pCR), i.e. cancer cell residues can still be observed under the microscope. The diagnosis of NON-pCR after the new assisted treatment consists mainly of the following steps and operations: o Video review: mammograms, mammograms, MRI, etc., are examined for visuals to assess changes in tumour size, morphology, blood flow, etc., compared to pre-treatment. Paralytic assessment: 4.o Surgery sample analysis: New assisted treatment is usually followed by surgical removal (e.g. mastectomy or lactation), and tumours and lymphomy are subject to detailed pathological examination. Underscope Residual Assessment: The pathologist will carefully examine the surgical specimens under the microscope to assess if there are any cancer cell residues. This is the gold standard for pCR and NON-pCR. NON-pCR refers to the presence of cancer cell residues. o Immunisation and Genetic Testing: Specific immunisation dyeing or genetic testing, as needed, to further the understanding of the biological properties and molecular stratification of tumours and to facilitate the development of follow-up treatment programmes. 5. Integrated assessment: o Multidisciplinary discussion (MDT): Integration of clinical, visual and pathological information, organization of a comprehensive discussion among multidisciplinary teams, including surgeons, oncologists, excursors, pathologists, etc., to determine the post-treatment status of patients and follow-up strategies. o Development of individualized treatment programmes: based on NON-pCR specifics, such as the number, location, biological characteristics, etc., of residual cancer cells, personalized follow-up programmes, such as adjustment of chemotherapy programmes, increased access to treatment or target-oriented treatment. It should be noted that NON-pCR does not mean that treatment has failed or is not prepared well. Many patients still have access to good treatment and long-term survival in NON-pCR. It is therefore important to fully assess the overall situation of patients, develop scientifically sound treatment plans and closely monitor changes in conditions during treatment and adjust treatment strategies in a timely manner.